Zai Lab In-licenses Novel EGFR Inhibitor in $233 Million Deal

Shanghai's Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. CLN-081 is an oral EGFR inhibitor currently being tested in a US Phase I/IIa trial that enrolled NSCLC patients with EGFR Ex20ins mutations. Zai develops novel targeted oncology and immuno-oncology therapies along with products addressing infectious diseases for China use. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //